Social Cognition in Youth Who Have a First Degree Relative With Schizophrenia

Sponsor
The Royal Ottawa Mental Health Centre (Other)
Overall Status
Recruiting
CT.gov ID
NCT04681807
Collaborator
(none)
36
1
2
27.3
1.3

Study Details

Study Description

Brief Summary

Social cognition is an individual's ability to perceive, process, understand, and react to other individuals in a social situation. Social cognition is impaired in individuals with schizophrenia, including difficulty recognizing others' emotions. A promising treatment avenue for emotion recognition problems in individuals with schizophrenia is continued practice with various facial expression recognition training programs. First degree relatives of someone with schizophrenia are considered at familial high risk (FHR) for the illness, because of its high level of heritability. It is therefore critical to explore if these emotion recognition training programs could also benefit people at FHR. In this current study, the investigators aim to explore the social-cognitive profiles and their neural correlates in FHR individuals. The investigators also aim to explore the potential efficacy of an emotion recognition intervention to improve this ability in FHR individuals.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Emotion Recognition Training
  • Behavioral: Active Control Training
N/A

Detailed Description

All participants will complete a battery of social cognitive tests as well as an fMRI scan to explore the neuronal correlates underlying lower social cognitive functioning observed in FHR individuals. FHR youth will be randomized into either a 4-session emotion recognition training exercise program on iPad or an active control training program on iPad that includes commercial games and control emotional attention bias training.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
36 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Patients will be randomized to either 7 visits over a period of 1 month of an emotion recognition training condition or 7 visits over a period of one month of active control training condition.Patients will be randomized to either 7 visits over a period of 1 month of an emotion recognition training condition or 7 visits over a period of one month of active control training condition.
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Masking Description:
Due to the nature of the intervention, treatment administrators will not be able to remain blind to group assignment; however, assessment staff, investigators, and participants will be blind to group assignment. Assessment staff and investigators will never be involved in the randomization or treatment procedures.
Primary Purpose:
Treatment
Official Title:
Social Cognition in Youth Who Have a First Degree Relative With Schizophrenia
Actual Study Start Date :
Jul 21, 2021
Anticipated Primary Completion Date :
Oct 31, 2023
Anticipated Study Completion Date :
Oct 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Emotion Recognition Training

Behavioral: Emotion Recognition Training
Participants will undergo 2 fMRI scans, one before and one after the training sessions. There will be 4 visits consisting of an emotion recognition training exercise on iPad, lasting for a period of ~1 hour each. (More details about each condition will be added after study completion to protect the blinding of participants) .

Active Comparator: Active Control Training

Behavioral: Active Control Training
Participants will undergo 2 fMRI scans, one before and one after the training sessions. There will be 4 visits consisting of a control training exercise on iPad, lasting for a period of ~1 hour each. (More details about each condition will be added after study completion to protect the blinding of participants) .

Outcome Measures

Primary Outcome Measures

  1. Change in emotion recognition performance from baseline - PENN Emotion Recognition Test [baseline and post treatment (1 month)]

    Penn Emotion Recognition test - tests the participant's ability to recognize emotion from facial expressions

  2. Change in brain activity during emotion recognition tasks from baseline [baseline and post treatment (1 month)]

    Brain activity as measured using task-based functional magnetic resonance imaging (fMRI).

Eligibility Criteria

Criteria

Ages Eligible for Study:
15 Years to 25 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Between (or equal to) 15-25 years of age

  • Ability to read/speak fluent English

  • Diagnosis of SZ, schizoaffective disorder or schizophreniform confirmed for 1st degree relative by referring psychiatrist or two reliable informants (using the adapted FIGS questionnaire).

Exclusion Criteria:
  • Diagnosis of mental health disorder

  • Significant neurological or medical disorders that may produce cognitive impairment

  • Current epilepsy or previous history of seizures

  • Previous head injury with current continuing symptoms (i.e., cognitive ability, dizziness, etc.)

  • Recent history of substance abuse or dependence (within past 3 months)

  • MRI contraindication (e.g. metallic head implant, history of seizure, pacemaker, pregnancy, etc.)

  • Current IQ < 70 as measured by the Wechsler Abbreviated Scale of Intelligence Scale (WASI)

Contacts and Locations

Locations

Site City State Country Postal Code
1 The Royal Ottawa Mental Health Centre Ottawa Ontario Canada K1Z 7K4

Sponsors and Collaborators

  • The Royal Ottawa Mental Health Centre

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Synthia Guimond, Principal Investigator, The Royal Ottawa Mental Health Centre
ClinicalTrials.gov Identifier:
NCT04681807
Other Study ID Numbers:
  • 2019033
First Posted:
Dec 23, 2020
Last Update Posted:
Apr 28, 2022
Last Verified:
Apr 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 28, 2022